Schizophrenia - A Pipeline Analysis Report | Technavio

Technavio has announced its new research report on the drug development pipeline for schizophrenia. (Graphic: Business Wire)

LONDON--()--Technavio has announced its new research report on the drug development pipeline for schizophrenia. The report comprises an in-depth analysis of the pipeline molecules under investigation within the defined data collection period to treat schizophrenia.

This report presents a comprehensive analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the market growth in the coming years.

This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing

Save more with Technavio. Buy 2 reports and get the third for FREE: View all Technavio’s current offers

Schizophrenia - market at a glance

Schizophrenia is a severe mental disorder, which is portrayed by significant disturbances in thinking, speech, observation, and the sense of self. It frequently incorporates psychotic experiences, for instance, hearing strange voices or hallucinations. Schizophrenia starts typically in the late youth or early adulthood. The symptoms of schizophrenia in young people are same as those in grown-ups, yet the condition might be hard to perceive.

According to a senior analyst at Technavio for central nervous system, “Around one-fourth of the adults in the US have mental illness, according to a research. In the US, the prevalence of schizophrenia is less than 1% of the population of adults. However, schizophrenia is rare in children, which can occur at a very early age even before puberty.”

Looking for more information on this market? Request a free sample report

Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.

Schizophrenia therapeutic segmentation

This market research report segments the schizophrenia therapeutic market based on therapies employed (monotherapy, combination therapy, and undisclosed), RoA (injection, intramuscular injection, intravenous, oral, oral + subcutaneous, subcutaneous, transdermal, and undisclosed), therapeutic modality (small molecule and undisclosed), targets for drugs under development (5-hydroxytryptamine (5HT), dopamine, 5HT+dopamine, alpha-7 nicotinic acetylcholine receptor, cannabinoid receptor, D-amino acid oxidase, gamma-aminobutyric acid (GABA) receptor, muscarinic receptor, N-methyl-D-aspartate (NMDA) receptor, undisclosed, and others), MoA (5HT, dopamine, 5HT+dopamine, alpha-7 nicotinic acetylcholine receptor agonist, cannabinoid receptor agonist/antagonist, D-amino acid oxidase inhibitors, GABA receptor modulator, NMDA agonist/antagonist, muscarinic receptor agonist/antagonist, undisclosed, and others), and recruitment status (recruiting, active not recruiting, completed, enrolling by invitation, not yet recruiting, and undisclosed).

Monotherapy includes the use of a single drug to treat a disorder or a disease. In the current pipeline, approximately 61% of the molecules are monotherapy.

Small molecules are chemically manufactured active substances that enter the cells due to their low molecular weight of fewer than 900 Daltons. In the current pipeline, around 79% of the molecules come under this category.

 

Save big with Technavio this May!

Find out what companies are venturing in to beat the heat this summer! Technavio indulges you with a massive 20% OFF on all

non-alcoholic beverages reports for the entire month.

OR

Technavio honors the achievements and efforts of Motherhood this Mother's Day by offering a whopping 30% OFF on all cosmetics and toiletry reports. Offer valid from 7th May for a limited period.

 

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at media@technavio.com.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
www.technavio.com

Release Summary

Technavio has announced its new research report on the drug development pipeline for schizophrenia.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
www.technavio.com